体外循环脱机困难患者静脉-动脉体外膜肺氧合的建立与转运管理
该观察性研究纳入2020年1月至2022年10月在皖南医学院第一附属医院(弋矶山医院)重症医学科收治的18例体外循环脱机困难、接受VA-ECMO辅助的体外循环手术患者。成功建立体外循环至VA-ECMO的平均时间为24.6±7.4分钟,初始血流量3.3±0.4 L/min,转运时间8.4±1.5分钟,ECMO辅助时长平均82.0±69.3小时;10例成功脱机、8例脱机失败。上机后4小时乳酸、pH值、平均动脉压、中心静脉血氧饱和度和血管活性-正性肌力评分较上机前均显著改善(均P<0.01)。脱机失败组上机前乳酸更高、体外循环时间更长、ECMO辅助时间更短;作者认为VA-ECMO是体外循环脱机困难的有效循环辅助,建立与转运依赖多学科协作,若无法成功脱离体外循环应尽早启动VA-ECMO。
要点
- 18例体外循环脱机困难患者接受VA-ECMO辅助,10例成功脱机、8例脱机失败;ICU存活8例、死亡5例、放弃治疗出院5例。
- 上机后4小时较上机前:乳酸10.5±7.0 vs. 15.2±6.8 mmol/L、pH值7.38±0.92 vs. 7.26±0.87、MAP 74.9±13.7 vs. 58.4±17.0 mmHg、ScvO2 0.678±0.065 vs. 0.611±0.061,均P<0.01;VIS 39.8±29.8 vs. 68.9±64.4,P<0.01。
- 脱机失败组较成功脱机组上机前乳酸更高(18.8±7.8 vs. 12.3±4.3 mmol/L,P<0.05)、体外循环时间更长(238.0(208.8,351.2)vs. 200.0(185.8,217.0)分钟,P<0.05)、ECMO辅助时间更短(19.5(11.0,58.8)vs. 94.5(65.8,179.8)小时,P<0.01)。
- 两组上机前pH值、ScvO2、MAP、VIS评分、ECMO初始血流量及建立时间差异无统计学意义。
- 成功建立体外循环至VA-ECMO的平均时间24.6±7.4分钟,初始血流量3.3±0.4 L/min,转运时间8.4±1.5分钟,ECMO辅助时长平均82.0±69.3小时;9例在建立和转运过程中发生不良事件。
适用人群与场景
- 2020年1月至2022年10月皖南医学院第一附属医院(弋矶山医院)重症医学科收治的体外循环手术后无法脱离体外循环、接受VA-ECMO辅助的体外循环手术患者。
- 共18例,男10例、女8例,平均年龄56.7±12.3岁,术前左心室射血分数(LVEF)0.46±0.10。
- 转为VA-ECMO辅助的主要原因:右心室收缩无力6例、全心收缩无力5例、左心室收缩无力4例、肺动脉高压2例、难治性心室颤动1例。
处置流程与药物剂量
- 体外循环脱机困难时建立VA-ECMO辅助,成功建立的平均时间为24.6±7.4分钟,初始血流量3.3±0.4 L/min,转运时间8.4±1.5分钟。
- ECMO辅助时长平均82.0±69.3小时;18例中10例成功脱机、8例脱机失败。
- 建立与转运过程依赖多学科协作(MDT)。
研究设计与关键结果
- 观察性研究,纳入18例体外循环脱机困难并接受VA-ECMO辅助的体外循环手术患者,记录VA-ECMO建立与转运过程、上机前后临床指标、VA-ECMO运行数据及临床结局,并按是否成功脱机分为成功脱机组与失败脱机组进行比较。
- 上机后4小时较上机前:乳酸10.5±7.0 vs. 15.2±6.8 mmol/L、pH值7.38±0.92 vs. 7.26±0.87、MAP 74.9±13.7 vs. 58.4±17.0 mmHg、ScvO2 0.678±0.065 vs. 0.611±0.061,均P<0.01;VIS 39.8±29.8 vs. 68.9±64.4,P<0.01。
- 脱机失败组较成功脱机组:上机前乳酸18.8±7.8 vs. 12.3±4.3 mmol/L(P<0.05)、体外循环时间238.0(208.8,351.2)vs. 200.0(185.8,217.0)分钟(P<0.05)、ECMO辅助时间19.5(11.0,58.8)vs. 94.5(65.8,179.8)小时(P<0.01)。
- 两组上机前pH值、ScvO2、MAP、VIS评分、ECMO初始血流量及建立时间差异无统计学意义。
- 18例中ICU存活8例、死亡5例、放弃治疗出院5例;9例在ECMO建立和转运过程中发生不良事件。
证据类型、等级与局限
- 观察性研究,样本量18例;局限:原文未报告局限性。
对床旁实践的改变
- 作者认为VA-ECMO是体外循环手术后无法脱机患者的有效循环辅助。
- 作者认为体外循环「桥接」至ECMO辅助的建立与转运依赖多学科协作(MDT)。
- 作者认为ECMO脱机成功率与乳酸和体外循环时长相关;若无法成功脱离体外循环,应尽早启动VA-ECMO。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the establishment method, coordination points and safe transport management strategy of vena-arterial extracorporeal membrane oxygenation (VA-ECMO) in patients with downtime difficulties during cardiopulmonary bypass (CPB).
METHODS: A observation study was conducted. The patients admitted to the department of critical care medicine of the First Affiliated Hospital of Wannan Medical College (Yijishan Hospital) from January 2020 to October 2022 were enrolled. These patients could not be separated from CPB and received VA-ECMO-assisted CPB surgery. The clinical data of the patients were recorded, including the basic information of the patients, the data of VA-ECMO establishment and transport process, the clinical indicators before and after VA-ECMO installation, the operation data of VA-ECMO and clinical outcomes. The experience was summarized from the aspects of extracorporeal membrane oxygenation (ECMO) establishment, transport process, team cooperation, and adverse events during transport. The clinical indicators before and after ECMO operation were compared. According to whether ECMO was successfully weaned, the patients were divided into a successful weaning group and a failure weaning group, and the clinical data between the two groups were compared.
RESULTS: Eighteen patients who underwent VA-ECMO-assisted CPB were enrolled, including 10 males and 8 females. The average age was (56.7±12.3) years old. Preoperative left ventricular ejection fraction (LVEF) was 0.46±0.10, and the main reasons for switching to VA-ECMO assistance included right ventricular systolic weakness in 6 cases, total cardiac systolic weakness in 5 cases, left ventricular systolic weakness in 4 cases, high pulmonary arterial pressure in 2 cases, and intractable ventricular fibrillation in 1 case. Among the 18 patients transferred from CPB to VA-ECMO, 10 cases were successfully weaned and 8 cases failed. In ICU, 8 cases survived, 5 cases died, and 5 cases gave up treatment and discharged. The average time for successful CPB to VA-ECMO establishment was (24.6±7.4) minutes, initial blood flow was (3.3±0.4) L/min, and transit time was (8.4±1.5) minutes. ECMO-assisted duration averaged (82.0±69.3) hours. Adverse events occurred in 9 patients during ECMO establishment and transfer. Post-ECMO onboarding for 4 hours, significant improvements were noted in blood lactic acid (Lac), pH value, mean arterial pressure (MAP), central venous oxygen saturation (ScvO2) as compared with pre-ECMO onboarding [Lac (mmol/L): 10.5±7.0 vs. 15.2±6.8, pH value: 7.38±0.92 vs. 7.26±0.87, MAP (mmHg, 1 mmHg ≈ 0.133 kPa): 74.9±13.7 vs. 58.4±17.0, ScvO2: 0.678±0.065 vs. 0.611±0.061, all P < 0.01], and vasoactive-inotropic score (VIS) was also decreased (39.8±29.8 vs. 68.9±64.4, P < 0.01). Compared with successful weaning group, the patients in the failed weaning group exhibited higher pre-machine Lac (mmol/L: 18.8±7.8 vs. 12.3±4.3, P < 0.05), longer CPB time [minutes: 238.0 (208.8, 351.2) vs. 200.0 (185.8, 217.0), P < 0.05], and shorter ECMO-assisted time [hours: 19.5 (11.0, 58.8) vs. 94.5 (65.8, 179.8), P < 0.01]. However, there was no statistically significant difference in pre-machine pH value, ScvO2, MAP, VIS score, and initial blood flow and establishment time of ECMO between the two groups.
CONCLUSIONS: VA-ECMO is an effective circulatory aid for CPB surgery that cannot be weaned after CPB. The establishment and transfer of CPB "bridge" to ECMO aid depends on multi-disciplinary treatment (MDT) cooperation. The success rate of ECMO weaning is related to the Lac and CPB duration. If it is not possible to detach from the CPB successfully, VA-ECMO should be initiated as early as possible.
参考来源
- Fang K, Da H, Sun R, et al. [Establishment and transfer management of veno-arterial extracorporeal membrane oxygenation in patients with difficult downtime during cardiopulmonary bypass surgery]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2024. PMID: 38813638. doi:10.3760/cma.j.cn121430-20230829-00714
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。